Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma by unknown
Deng et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:96 
DOI 10.1186/s13046-015-0208-8RESEARCH Open AccessExpression and clinical significance of
annexin A2 and human epididymis protein
4 in endometrial carcinoma
Lu Deng1, Yiping Gao1,2, Xiao Li1, Mingbo Cai1,3, Huimin Wang1, Huiyu Zhuang1,4, Mingzi Tan1, Shuice Liu1,
Yingying Hao1 and Bei Lin1*Abstract
Background: It is well-known that the treatment and monitoring methods are limited for advanced stage of
endometrial carcinoma. Biological molecules with expression changes during tumor progression become potential
therapeutic targets for advanced stage endometrial carcinoma. Annexin A2 (ANXA2) has been reported to be
overexpressed in recurrent endometrial carcinoma, and the expression of human epididymis protein 4 (HE4) is
upregulated in endometrial carcinoma. What’s more, ANXA2 and HE4 interacted in ovarian cancer and promoted
the malignant biological behavior. We speculated that their interaction may exist in endometrial carcinoma as well.
We evaluated the expression and the correlation relationship of ANXA2 and HE4 in endometrial carcinoma.
Methods: The expression of ANXA2 and HE4 protein in 84 endometrial carcinoma, 30 endometrial atypical
hyperplasia, and 18 normal endometrial tissue samples were then measured using an immunohistochemical assay
in paraffin embedded endometrial tissues. The structural relationship between ANXA2 and HE4 was explored by
immunoprecipitation and double immunofluorescent staining.
Results: ANXA2 and HE4 co-localized in both endometrial tissues and endometrial carcinoma cells. ANXA2 and HE4
were expressed in 95.2 % and 85.7 % of the the endometrial carcinoma, respectively, which were significantly
higher than normal endometrium (55.6 % and 16.7 %, both p < 0.05). The expression of ANXA2 and HE4 was significantly
correlated with FIGO stage, degree of differentiation, myometrial invasion, and lymph node metastasis. ANXA2 was an
independent risk factor for the prognosis of endometrial carcinoma (p < 0.05, hazard ratio [HR] = 8.004). The expression
of ANXA2 and HE4 was positively correlated (Spearman correlation coefficient = 0.228, p < 0.05). HE4 was an
independent factor for ANXA2 in multivariate linear regression model (p < 0.05).
Conclusion: We revealed the co-localization of ANXA2 and HE4 in endometrial carcinoma. Expression levels of
ANXA2 and HE4 were closely related to the malignant biological behavior of endometrial carcinoma, and ANXA2
was an independent risk factor for poor prognosis. The expression of ANXA2 and HE4 can affect each other.
Keywords: Annexin A2, Human epididymis protein 4, Endometrial carcinoma, Immunohistochemistry, Prognosis* Correspondence: linbei88@hotmail.com
1Department of Gynaecology and Obstetrics, Shengjing Hospital affiliated to
China Medical University, No. 36 Sanhao Street, Heping District, Shenyang
110004, Liaoning, China
Full list of author information is available at the end of the article
© 2015 Deng et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Deng et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:96 Page 2 of 11Background
Endometrial carcinoma is one of the most common ma-
lignant tumors of the female reproductive system, the
mortality of which is only second to ovarian carcinoma
in developed countries; the incidence of endometrial car-
cinoma is increasing year-by-year [1]. Endometrial car-
cinoma most often affects postmenopausal women, the
incidence among younger women has been on the rise
in recent years. Many patients with endometrial carcin-
oma are diagnosed early due to irregular vaginal bleed-
ing, and usually have a good prognosis. Treatment
options are limited for patients with metastases in ad-
vanced stages or recurrent endometrial carcinoma; there
is no significant effect using combined chemotherapy
and radiotherapy or novel molecular-targeted drugs [2, 3].
The known prognostic factors of endometrial carcinoma
include degree of tumor differentiation, International
Federation of Gynecology and Obstetrics (FIGO) stage,
histologic type, and estrogen receptor (ER) positivity
[4–6], but do not predict patient outcome or guide
treatment. Biological molecules with expression changes
during tumor progression become potential therapeutic
targets for advanced stage endometrial carcinoma. Re-
searchers have identified a large number of new bio-
markers that can be used to evaluate the prognosis of
endometrial carcinoma and monitor recurrences [7–12],
and some molecules associated to the tumorigenesis of
endometrial carcinoma [13]; however, no biomarker has
been used in clinical application.
Annexin A2 (ANXA2) is a member of the annexin
family, and is also known as p36. ANXA2 has a relative
molecular mass of 36 kDa and the gene is located on the
long arm of chromosome 15 [14]. ANXA2 exists in
many cell types and regulates a number of biological
functions, including membrane transport, signal trans-
duction, cell differentiation, and apoptosis [15]. A large
number of studies have shown a significant change in
the level of ANXA2 expression in tumor tissues [16].
The expression of ANXA2 is significantly increased in
the malignant tumors of the blood, and breast, cervical,
and pancreatic cancers, and is also related to drug resist-
ance and poor prognosis. The expression of ANXA2 is
decreased in esophageal squamous cell carcinoma and
osteosarcomas, while the change of expression in pros-
tate cancer is controversial [16, 17]. ANXA2 is closely
related to the occurrence and development of tumors,
and also plays an important role in angiogenesis, prolif-
eration, apoptosis, adhesion, invasion, and migration in
malignant tumors [18].
Human epididymis protein 4 (HE4), also known as
whey acidic protein (WFDC2), is an ovarian cancer
tumor marker identified by genomic and proteomic
screening [19]. HE4 was designated as a serum marker
for ovarian cancer in 2003, and aroused the attention ofresearchers due to its high sensitivity and specificity
[20]. HE4 is a secreted protein, with a much smaller mo-
lecular weight compared to CA-125, and has a better
sensitivity, specificity, positive likelihood ratio, and nega-
tive likelihood ratio than CA-125 in the diagnosis of
ovarian cancer [21]. Subsequent research has shown that
the overexpression of HE4 not only exists in patients
with ovarian cancer, but has also been observed in pa-
tients with transitional cell carcinoma, lung adenocarcin-
oma, breast cancer, pancreatic cancer, endometrial
carcinoma and so on [22, 23].
In the preliminary study, a known protein annexin a2
was discovered as a binding partner of HE4 by mass
spectrometry in ovarian cancer cells. We used co-
immunoprecipitation assays and GST-pulldown to iden-
tify their interaction and found out the interaction site is
located after the 26th amino acid at the N terminus of
ANXA2. The expression of ANXA2 and HE4 were up-
regulated simultaneously and their overexpression pro-
moted the malignant behavior of ovarian cancer [24, 25].
Researches showed that, the expression of ANXA2 and
HE4 were up-regulated in endometrial carcinoma, re-
spectively [26, 27]. In 2014, Alonso et al. [26] reported
that detection of recurrent endometrial carcinoma could
be achieved by comparing the level of ANXA2 expres-
sion between recurrent and primary lesions. It was also
reported that serum HE4 can be used as a prognostic
marker and pre-operative risk evaluation index in endo-
metrial carcinoma patients [27]. Does the interaction be-
tween ANXA2 and HE4 exist in endometrial carcinoma
and promote its malignant biological behavior? The two
molecules are considered to be closely related to the
tumorigenesis and progression of malignant tumors.
However, studies so far have not tested the expression of
ANXA2 and HE4 in endometrial carcinoma, simultan-
eously. So does the interaction of them in endometrial car-
cinoma. In the current study, for the first time, we
simultaneously compared the expression level of ANXA2
and HE4 in endometrial tissues by immunohistochemistry
assays, analyzed the correlation of the two molecules and
investigated the effects of them on the development of
endometrial carcinoma, and the interaction between
ANXA2 and HE4 in the progression of endometrial car-
cinoma. We hope this study will contribute to the diagno-
sis, treatment and prognosis assessment of endometrial
caicinoma.
Materials and methods
Patients and paraffin-embedded tissue samples
The study was approved by the Research Ethic Board at
Shengjing Hospital affiliated to China Medical Univer-
sity. Our study population consisted of 132 patients and
the specimens were collected during operation from the
Department of Obstetrics and Gynecology of Shengjing
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2004 and 2013. The paraffin-fixed pathologic specimens
had histopathologic-confirmed diagnoses by in-house
experts, as follows: endometrial carcinoma, n = 84;
atypical hyperplasia of endometrium (mild hyperplasia,
n = 8; moderate hyperplasia, n = 9; and severe hyperpla-
sia, n = 13), n = 30; and endometrium (secretory and
proliferative phase, n = 9 each), n = 18 (Table 1). The
normal endometrium specimens were collected from
patients with undesired fertility who had vaginal hyster-
ectomies of the entire uterus or entire uterus and bilat-
eral adnexa due to cervical lesions, with no uterine
myomas, ovarian chocolate cysts, or other estrogen-
dependent diseases in the atypical hyperplasia and nor-
mal endometrium groups. Patients in the endometrial
carcinoma group were 36–79 years of age with an aver-
age age of 58.93 years, patients in the endometrial atyp-
ical hyperplasia group were 30–66 years of age with an
average age of 45.30 years, and patients in the normal
endometrium group were 39–53 years of age with an
average age of 44.06 years; no statistically significant
difference existed among the average ages of each
group (p > 0.05). All of the patients had primary endo-
metrial carcinomas with complete clinical and patho-
logic data, and no patients received pre-operative
chemotherapy and/or hormone therapy (clinicopatho-
logical parameters seen in Table 2).Cell culture
An ovarian cancer cell line (CaoV-3) and endometrial car-
cinoma cell lines (HEC-1A and Ishikawa) were purchased
from Cell Culture Collection of Shanghai and propagated
in McCoy’s 5A modified medium with 10 % fetal bovine
serum. Cell culture was according to the manufacturer’s
protocol. All the cell lines were grown at 37 °C in a 5 %
CO2/95 % air atmosphere and were revived every 3 to
4 months.Table 1 Expression of ANXA2 and HE4 in different endometrial tissu
Groups Cases ANXA2
- + ++ +++ P
Malignant 84 4 25 27 28 9
Atypical 30 5 9 7 9 8
Severe 13 2 3 3 5 8
Moderate 9 1 3 3 2 8
Mild 8 2 3 1 2 7
Normal 18 8 2 1 7 5
Proliferative 9 5 1 0 3 4
Secretory 9 3 1 1 4 6
a,bpositive ANXA2 cases in malignant and atypical, respectively, compared with nor
c,dpositive HE4 cases in malignant compared with atypical and normal group, respe
epositive HE4 cases in atypical group campared with normal group, p < 0.05 (pe = 0.Immunohistochemistry and immnocytochemistry staining
The endometrial tissue specimens were dissected using
5-μm serial consecutive sections. Immunohistochemical
staining was carried out as previously described [24].
Each tissue had two serial sections. Expression patterns
of HE4 and ANXA2 in ovarian carcinoma tissues were
analyzed via immunohistochemical streptavidinperoxi-
dase staining. Positive and negative immunohistochem-
istry controls were routinely employed. Normal
epididymis tissue served as a positive control for HE4,
while breast cancer tissue was used as the positive con-
trol for ANXA2 antigen. The negative control was in-
cubated with rabbit IgG (Bioss, China) instead of
primary antibody. The working concentrations of pri-
mary antibodies against HE4 and ANXA2 used were
1:40 (Abcam, Rabbit polyclonal to HE4) and 1:1200
(Abcam, Rabbit polyclonal to ANXA2), respectively.
The empirical procedure was performed based on the
manufacturer's instructions.
Cells at exponential phase of growth were digested by
0.25 % trypsin and cultured in medium containing 10 %
FBS. Adherent cells with 30-40 % confluence were washed
twice with cold PBS when growing in a single layer, and
fixed with 4 % para- formaldehyde for 30 min. The rest
steps were the same as immunohistochemistry.
We consider a positive result if there are buffy granules
in the cell membrane and cytoplasm. According to the
chromatosis intensity, no pigmentation, light yellow, buffy,
and brown are scored 0, 1, 2, and 3, respectively. We
choose 5 high-power fields in series from each slice, then
score them and take the mean percentage of the chroma-
tosis cells: chromatosis cells that account less than 5 % are
0, 5 % to 25 %: 1, 26 % to 50 %: 2, 51 % to 75 %: 3, and
greater than 75 %: 4. Multiply these 2 numbers: 0 to 2 is
considered (−); 3 to 4, (+); 5 to 8, (++); and 9 to 12, (+++).
The scoring and corresponding images were presented
(Additional file 1: Figure S1). Two pathologists read the
sections to control error, independently.es
HE4
ositive (%) - + ++ +++ Positive (%)
5.2 %a 12 34 25 13 85.7 %c,d
3.3 %b 10 13 7 0 66.7 %e
4.6 % 3 5 5 0 76.9 %
8.9 % 2 5 2 0 77.8 %
5.0 % 5 3 0 0 37.5 %
5.6 % 15 3 0 0 16.7 %
4.4 % 8 1 0 0 11.1 %
6.7 % 7 2 0 0 22.2 %
mal group, both p < 0.05 (pa < 0.001, pb = 0.049)
ctively, both p < 0.05 (pc = 0.023, pd < 0.001)
001)
Table 2 Relationships between the expression of ANXA2, HE4 and clinicopathological parameters of 84 endometrial carcinoma
patients
Parameters Cases ANXA2 HE4
Positive exp. (%) P-value High exp. (%) P-value Positive exp. (%) P-value High exp. (%) P-value
Age at diagnosis
< 59 42 39(92.9 %) p > 0.05 26(61.9 %) p > 0.05 36(85.7 %) p > 0.05 18(42.9 %) p > 0.05
≥ 59 42 41(97.6 %) 29(69.0 %) 36(85.7 %) 20(47.6 %)
FIGO stage
I 53 49(92.5 %) p > 0.05 29(54.7 %) pI-II/III-IV = 0.001 45(84.9 %) p > 0.05 20(37.7 %) pI-II/III-IV = 0.013
II 7 7(100 %) 4(57.1 %) 5(71.4 %) 2(28.6 %)
III 21 21(100 %) 19(90.5 %) 19(90.5 %) 13(61.9 %)
IV 3 3(100 %) 3(100 %) 3(100.0 %) 3(100 %)
Pathologic type
Endometiod
39 35(89.7 %) p > 0.05 23(59.0 %) p > 0.05 34(87.2 %) p > 0.05 18(46.2 %) p > 0.05
Serous 19 19(100 %) 13(68.4 %) 15(78.9 %) 6(31.6 %)
Clear cell 17 17(100 %) 12(70.6 %) 16(94.1 %) 8(47.1 %)
Othersa 9 9(100 %) 7(77.8 %) 7(77.8 %) 6(66.7 %)
Differentiation
Well 17 14(82.4 %) pwell/poor = 0.020 4(23.5 %) pwell/mod. = 0.003 13(76.5 %) p > 0.05 3(17.6 %) pwell/mod. = 0.009
Moderate 24 23(95.8 %) 17(70.8 %) pwell/poor < 0.001 22(91.7 %) 14(58.3 %) pwell/poor = 0.026
Poor 43 43(100 %) 34(79.1 %) 37(86.0 %) 21(48.8 %)
ERb
- 45 44(97.8 %) p > 0.05 33(73.3 %) p−/+ = 0.031 40(88.9 %) p > 0.05 21(46.7 %) p > 0.05
+ 27 24(88.9 %) 13(48.1 %) 22(81.5 %) 11(40.7 %)
Unknown 12 12(100 %) 9(75.0 %) 10(83.3 %) 6(50.0 %)
PRc
- 43 43(100 %) p−/+ = 0.023 33(76.7 %) p−/+ = 0.006 39(90.7 %) p > 0.05 21(48.8 %) p > 0.05
+ 29 25(86.2 %) 13(44.8 %) 24(82.8 %) 12(41.4 %)
Unknown 12 12(100 %) 9(75.0 %) 9(75.0 %) 5(41.7 %)
Muscular invasion
< 1/2 51 47(92.2 %) p > 0.05 28(54.9 %) p = 0.011 42(82.4 %) p > 0.05 17(33.3 %) p = 0.006
≥ 1/2 33 33(100 %) 27(81.8 %) 30(90.9 %) 21(63.6 %)
LN metastasisd
- 50 48(96.0 %) p > 0.05 29(58.0 %) p−/+ = 0.003 44(88.0 %) p > 0.05 18(36.0 %) p−/+ = 0.016
+ 19 19(100 %) 18(94.7 %) 18(94.7 %) 13(68.4 %)
Unknown 15 13(86.7 %) 8(53.3 %) 10(66.7 %) 7(46.7 %)
a”Others” including 4 mucous carcinoma, 2 squamous carcinoma, 2 undifferentiated carcinoma, 1 small cell carcinoma
b12 patients without ER detection
c12 patients without PR detection
d15 patients without lymphadenectomy
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Ice-cold RIPA buffer (1 ml) was added to the endometrial
carcinoma cells and ovarian cancer cells, followed by
incubation for 30 min at 4 °C. After centrifugation at
15,000 × g for 30 min at 4 °C, the supernatant was col-
lected and treated with 2 μg of mouse anti-ANXA2 mono-
clonal (Proteintech, Chicago, America) or goat anti-HE4
polyclonal antibody (Santa Cruz Biotechnology, Inc., SantaCruz, CA, USA) for 3 h at 4 °C. Then, 20 μl of protein
A/G PLUS-Agarose (Santa Cruz Biotechnology, Inc.)
was added, followed by incubation on a rocker platform
overnight at 4 °C. The primary antibody was replaced
by mouse or goat IgG (Bioss, China) as negative con-
trol. Immunoprecipitates were subsequently subjected
to 12 % SDS gel electrophoresis and analyzed via west-
ern blot using rabbit HE4 monoclonal (Abcam) and
Fig. 1 Expression and interaction of ANXA2 and HE4 in ovarian and
endometrial cancer cells. Legends: Western blot detected the
expression of ANXA2 and HE4 in ovarian cancer and endometrial
cancer cell lines (CaoV3, HEC-1A, Ishikawa) (A). Cell lyste from CaoV3
and Ishikawa and HEC-1A cell lines was immunoprecipitated with
anti-ANXA2 antibody (B) and anti-HE4 antibidy (C) and then
immunoblotted with anti-HE4 antibody and anti-ANXA2 antibody, “IgG”
representing the negtive control. “Input” was total cell lysate of CaoV3
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Proteins were visualized using ECL reagent (Thermo
scientific ECL). The experiments were repeated three
times.
Double-labeling immunofluorescence method
The endometrial tissue sections displayed positive expres-
sion of ANXA2 and HE4 in immunohistochemistry and
endometrial carcinoma cell lines HEC-1A and Ishikawa
were selected for the double-labeling immunofluorescence
method. The sections and cells were simultaneously incu-
bated with primary antibodies against HE4 (1:50 [rabbit];
Abcam) and ANXA2 (1:50 [mouse]; Proteintech). The
primary antibody was replaced by rabbit or mouse IgG
for negative controls. The working concentrations of
fluorescein isothiocyanate (FITC) and tetraethyl rhoda-
mine isothiocyanate (TRITC) were 1:50. Nuclei were
counterstained with 4′,6-diamidino-2-phenylindole (DAPI).
The empirical procedure was performed according to
the manufacturer's instructions.
Statistical analysis
The SPSS17.0 software system (SPSS, Inc., Chicago, IL,
USA) was used for statistical analysis. χ2 analysis, vari-
ance analysis and t-test were employed. Cox regression
model was used for analysis of risk factors. Kaplan–
Meier and log-rank methods were used to analyze and
compare survival curves. Spearman correlation analysis
and regression model were used to analyze the correl-
ation between the two proteins. A bilateral p < 0.05 was
considered statistically significant.
Results
Co-expression of ANXA2 and HE4 in endmetrial cancer
tissue sections and cells
Results of western blot and immunocytochemical testing
confirmed the expression of ANXA2 and HE4 in endo-
metrial carcinoma cell lines (Ishikawa and HEC-1A;
Figs. 1A and 2A). Then, co-immunoprecipitation testing
detected the interaction between ANXA2 and HE4 in
the two cell lines (Fig. 1B and C). Immunofluorescence
revealed co-expression of ANXA2 labeled by red fluores-
cence and HE4 labeled by green fluorescence in the cell
membrane and cytoplasm of endometrial carcinoma cell
lines (Fig. 2B) and different endometrial tissues (Fig. 3B),
and the overlapping orange fluorescence observed at the
expression sites suggested co-localization of ANXA2 and
HE4.
Expression of ANXA2 and HE4 in different endometrial
tissues
ANXA2 and HE4 coloration mainly occurred in the cell
membrane, which was also observed in the cytoplasm
(Fig. 3A). The rate of positive expression of ANXA2 inendometrial carcinoma, atypical hyperplasia, and normal
endometrium tissues was 95.2 % (80/84), 83.3 % (25/30),
and 55.6 % (10/18), respectively (Table 1). The rates of
positive expression in malignant and atypical hyperplasia
tissues were significantly higher than the rates of positive
expression in normal tissues (both p < 0.05) (Table 1).
The positive rates of expression of ANXA2 in the mod-
erate and severe atypical hyperplasia groups were 88.9 %
(8/9) and 84.6 % (11/13), respectively, which were higher
than the mild group (75.0 % [6/8]; both p > 0.05)
(Table 1). The positive rate of expression of secretory
Fig. 2 Expression and co-localization of ANXA2 and HE4 in cancer
cells. Legends: A Expression of ANXA2 and HE4 in ovarian cancer
cells CaoV3 (a, d) and endometrial camcer cells HEC-1A (b, e), Ishikawa
(c, f), detected by immunocytochemistry. B Double-labeling
immunofluoscence showed the colocalization of HE4 and ANXA2
in HEC-1A (a ~ d) and Ishikawa (e ~ h). The color of “red” represents
ANXA2; “green” represents HE4; “blue” represents nucleus; “orange”
represents the colocalization of ANXA2 and HE4. The scale ruler
represents 50 μm; picture magnification is 400 × (A, B) and then
magnified twice in the small box at the top-left corner (B)
Fig. 3 Expression and co-localization of ANXA2-HE4 in endometrial
tissues. Legends: A Immunohistochemical micrographs of ANXA2
and HE4 in malignant tissues (a, d), atypical tissues (b, e), normal tissues
(c, f); The scale ruler represents 100 μm; picture magnification is 200×
and 400× for the small box at the top-left corner. B Colocalization of
ANXA2 and HE4 detected by double-labeling immunofluoscence in
malignant tissues (a ~ d), atypical tissues (e ~ h), and normal tissues
(i ~ l). The color of “red” represents ANXA2; “green” represents HE4;
“blue” represents nucleus; “orange” represents the colocalization of
ANXA2 and HE4. The scale ruler represents 50 μm; picture magnification
is 400× and then magnified twice in the small box at the top-left corner
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than proliferative endometrium (44.4 % [4/9]; p > 0.05)
(Table 1).
The positive rate of expression of HE4 in the endo-
metrial carcinoma group was 85.7 % (72/84), which was
significantly higher than the atypical hyperplasia 66.7 %
(20/30) and normal control groups 16.7 % (3/18; both
p < 0.05) (Table 1). The positive rate of expression of
HE4 in atypical hyperplasia was also significantly higher
than normal control groups (p < 0.05). The positive rates
of expression of HE4 in the moderate and severe atypical
hyperplasia groups were 77.8 % (7/9) and 76.9 % (10/13),
respectively, which were higher than the mild atypical
hyperplasia group (37.5 % [3/8]; both p > 0.05) (Table 1).
The positive rate of expression in secretory phase endo-
metrium was 22.2 % (2/9), which was slightly higher
than the proliferative phase endometrium (11.1 % [1/9];
p > 0.05) (Table 1).
Relationship between the expression of ANXA2/HE4 and
the clinicopathologic parameters of endometrial
carcinoma
The study included 84 cases of endometrial carcinoma
with positive expression of ANXA2 in well, moderately,
and poorly differentiated groups (82.4 % [14/17], 95.8 %
[23/24], and 100 % [43/43], respectively), which increasedwith the reduction in the degree of differentiation
(Table 2). The positive rate of expression of ANXA2 in the
well differentiated group was significantly lower than the
poorly differentiated group (p < 0.05) (Table 2). The ex-
pression rate of ANXA2 in the PR-negative group (100 %
[43/43]) was significantly higher than the PR-positive
group (86.2 % [25/29], p < 0.05) (Table 2). When the cases
of endometrial carcinoma were further divided into high
(++/+++) and low ANXA2 expression groups (−/+), the
high expression rate of ANXA2 in stage III–IV endomet-
rial carcinoma patients was 91.7 % (22/24), which was sig-
nificantly higher than stage I–II patients (55.0 % [33/60],
p < 0.05) (Table 2). With a reduction in the degree of dif-
ferentiation, the high expression rate of ANXA2 increased
gradually; specifically, the high expression rate in mod-
erately and poorly differentiated groups were 70.8 %
(17/24) and 79.1 % (34/43), respectively, which were
significantly higher than the well differentiation group
(23.5 % [4/17]; both p < 0.05) (Table 2). High expression
rate of ANXA2 in the ER- and PR-negative groups were
73.3 % (33/45) and 76.7 % (33/43), respectively, which
were significantly higher than the ER- and PR-positive
groups (48.1 % [13/27] and 44.8 % [13/29], respectively;
both p < 0.05) (Table 2). The high expression rate of
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81.8 % (27/33), which was significantly higher than the
superficial myometrial invasion group (54.9 % [28/51];
p < 0.05) (Table 2). The high expression rate of ANXA2
in the lymph node metastasis group was 94.7 % (18/19),
which was significantly higher than the negative lymph
node metastasis group (58.0 % [29/50]; p < 0.05)
(Table 2). No significant difference in the expression of
ANXA2 was detected among the different pathologic
tumor-types (p > 0.05) (Table 2).
Similar to ANXA2, the high expression rate of HE4 in
stage III–IV endometrial carcinoma was 66.7 % (16/24),
which was significantly higher than stage I–II (36.7 %
[22/60]; p < 0.05) (Table 2). The high expression rate of
HE4 in moderately and poorly differentiated carcinoma
was 58.3 % (14/24) and 48.8 % (21/43), respectively,
which was significantly higher than well-differentiated
cancer (17.6 % [3/17]; both p < 0.05) (Table 2). The high
expression rate of HE4 in the positive lymph node me-
tastasis group was 68.4 % (13/19), which was signifi-
cantly higher than the negative lymph node metastasis
group (36.0 % [18/50]; p < 0.05) (Table 2). The high ex-
pression rate of HE4 in the deep muscular layer inva-
sion group was 63.6 % (21/33), which was significantly
higher than the superficial myometrial invasion group
(33.3 % [17/51]; p < 0.05) (Table 2). No significant dif-
ference in the expression of HE4 was detected among
the different pathologic tumor-types, and ER and PR
expression (p > 0.05) (Table 2).
ANXA2 and HE4 overexpression in endometrial carcinoma
predicts patient survival
Until November 2014, with a follow-up time of 16–126
months, among the 84 patients with endometrial carcin-
oma, 19 died of recurrent cancer, 3 survived with tumor
recurrences, 43 survived without tumor recurrence, and
the other 19 were lost to follow-up. The mortality and
recurrence rates of the ANXA2 and HE4 high expres-
sion group were 42.9 % (18/42) and 47.6 % (20/42), and
44.8 % (13/29) and 51.7 % (15/29), respectively, which
were significantly higher than the low expression group
(4.3 % [1/23] and 8.7 % [2/23], and 16.7 % [6/36] and
19.4 % [7/36], respectively; all p < 0.05) (Additional file 2:
Table S1).
Univariate Kaplan–Meier analysis revealed that high
expression of ANXA2 and HE4 were significantly corre-
lated with a shortened overall survival (both p < 0.05)
(Fig. 4 and Table 3). The average survival time of the
ANXA2 and HE4 high expression group was 35.40 and
37.14 months, while the average survival time of the low
expression group was 50.26 and 43.50 months, respect-
ively. In addition, age (<59 years vs. ≥ 59 years), FIGO
staging (I–II vs. III–IV), degree of differentiation (well -
moderate vs. poor), and depth of myometrial invasion(<1/2 vs. > 1/2) were all associated with a poor prognosis
(all p < 0.05) (Fig. 4 and Table 3).
Based on univariate analysis, the multivariate Cox re-
gression model was used for the analysis of prognostic
risk factors; the results are listed in Table 4. Age at diag-
nosis, FIGO stage, differentiation, depth of invasion, and
the level of expression of ANXA2 and HE4 were in-
cluded in the analysis model. Multivariate Cox regres-
sion analysis showed that overexpression of ANXA2 and
advanced FIGO staging were independent risk factors
for the prognosis of endometrial carcinoma (Table 3).
Correlation between the expression of ANXA2 and HE4
There were 2, 2, 10, and 70 patients in the ANXA2-/HE4-,
ANXA2-/HE4+, ANXA2+/HE4-, and ANXA2+/HE4+
groups, respectively. Correlation analysis showed that
there was a positive correlation between the expression of
ANXA2 and HE4 in endometrial carcinoma (Spearman
correlation coefficient RS = 0.228, p = 0.037) (Table 4).
Univariate linear regression analysis showed that the
immunoactivity of ANXA2 and HE4 can affect each
other (both p < 0.05) (Table 5). As was presented in
Table 2, FIGO stage, differentiation degree, ER expres-
sion, PR expression, muscular invasion degree and
lymph nodes metastasis were significant affective factors
of ANXA2 expression. In multivariate linear regression
analysis of ANXA2 expression score (from 0 to 12), the
results showed that HE4 expression and differentiation
degree or muscular invasion were independent factors of
ANXA2 expression. Multivariate analysis showed mus-
cular invasion was independent factors of HE4 expres-
sion (Table 5).
Discussion
ANXA2 is a calcium-dependent phospholipid-binding
protein, widely existing on the cell surface membranes
of tumor cells, endothelial cells, macrophages, and
monocytes. ANXA2 is involved in membrane transport
and a series of membrane surface calmodulin-dependent
biological functional activities, including cell migration,
inflammation, fibrinolysis, exocytosis, endocytosis, signal
transduction, and cellular proliferation, differentiation,
and apoptosis [15]. As a co-receptor of tissue plasmino-
gen activator and plasminogen, ANXA2 promotes the
formation and activation of plasmin and the downstream
matrix metalloproteinases, and promotes extracellular
matrix remodeling, angiogenesis, invasion, and metasta-
sis of tumor cells. ANXA2 also interacted with P-gp and
HAb18G/CD147 to promote malignant biological behav-
ior of malignant tumors, such as drug resistance, prolif-
eration, and adhesion. ANXA2 plays an important role
in biological activity and tumor progression [18, 28, 29].
Recently, our team discovered another ANXA2 inter-
































































































































































Fig. 4 Univariate Kaplan–Meier analysis of endometrial cancinoma. Legends: The blue line means patients with low ANXA2 expression (A) low
HE4 expression (B) well-moderate differentiated (C) I ~ II surgical stage (D) superficial muscular infiltration (E) and yonger patients (F) showed
significantly longer overall survival
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specific expression in ovarian cancer [20]. Through mass
spectrometry analysis, co-immunoprecipitation, and im-
munofluorescence, we confirmed the interaction between
these two proteins in ovarian cancer cells, and found that
the combination of ANXA2 and HE4 activated the MAPK
and FOCAL signaling pathways to promote the invasion
and migration of ovarian cancer cells [24].
This study examined the expression of ANXA2 and HE4
in endometrial carcinoma cells using western blot andTable 3 Survival analysis and prognosis analysis of endometrial
carcinoma. Univariate Kaplan-Meier analysis of the prognosis of
endometrial carcinoma
Variable Characteristics (Log-rank) p-value
Age at diagnosis <59y vs. ≥59y 0.020
FIGO stage I-II vs. III-IV <0.001
Differentiation grade Well-mod. vs. poor 0.027
Muscular invasion <1/2 vs. ≥1/2 0.002
ANXA2 Low vs. high 0.002
HE4 Low vs. high 0.018
Multivariate Cox regression analysis of patients with endometrial
carcinoma
Variables p-value Hazard ratio (95 % CI)
FIGO stage (I-II vs III-IV) 0.002 4.593 (1.763-11.964)
ANXA2 (low vs high) 0.046 8.004 (1.036-61.844)immunocytochemistry, and confirmed their inter-
action in endometrial carcinoma cells through co-
immunoprecipitation and double-labelling immuno-
fluorescence. We further examined the expression
levels of ANXA2 and HE4, and showed that the levels
of ANXA2 expression in endometrial carcinoma and
atypical hyperplasia were significantly higher than nor-
mal endometrium (Table 1), and high ANXA2 expres-
sion was related to lymph node metastasis and depth
of myometrial invasion (Table 2). The level of HE4 ex-
pression in endometrial carcinoma was also signifi-
cantly elevated, with a correlation detected between
the expressions of these two proteins. Therefore, we
hypothesized that ANXA2 interacted with HE4 to pro-
mote tumor invasion and metastasis in endometrial
carcinoma. The results of our study showed that the
ANXA2 and HE4 expression in stage III–IV endomet-
rial carcinoma patients was higher than stage I–IITable 4 The correlation between ANXA2 and HE4 expression in
endometrial carcinoma. (the Spearman correlation coefficient rs
was 0.228, p =0.037)
ANXA2 Cases HE4
Negative Positive
Negative 4 2 2
Positive 80 10 70
Cases 84 12 72
Table 5 Linear regression analysis of ANXA2 and HE4 expression
ANXA2 score HE4 score
Univariate Multivariate Univariate Multivariate
β p β p β p β p
HE4 score 0.267 0.014 0.251 0.018b
ANXA2 score 0.268 0.014 0.202 0.064c
FIGO 0.828 0.020 0.601 0.096
Differentiation 1.657 0.016 1.555 0.020b 0.409 0.559
ER −0.815 0.303 0.207 0.791
PR −1.665 0.031 0.011 0.988
Muscular invasion 1.693 0.016 2.006 0.009a 1.959 0.005 1.959 0.005c
LN metastasis 1.521 0.074 1.387 0.111
arepresents the multivariate regression analysis when ANXA2 score was dependent variate, including HE4 score, FIGO, differentiation, PR and muscular invasion as
independent variables
brepresents the results of model 2 in multivariate regression analysis when excluding PR as independent variables
crepresents the multivariate regression analysis when HE4 score was dependent variate, including ANXA2 score and muscular invasion as independent variables
Deng et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:96 Page 9 of 11patients (Table 2), which was correlated with FIGO
staging and the prognosis of survival in patients with
endometrial carcinoma (Table 3), as further supported
by studies investigating the role of ANXA2 and HE4
in other tumors [30–33].
Currently, the studies investigating ANXA2 in endo-
metrial tissues are limited, with only a few studies show-
ing that ANXA2 might play an important role in
endometriosis [34], adenomyosis angiogenesis [35], and
embryo implantation [36, 37]. In 2009, Dominguez et al.
[36] detected significantly different expression of
ANXA2 during the implantation window by protein
mass spectrometry analysis. The investigation further
showed [37] inhibition of ANXA2 expression signifi-
cantly eliminated embryo adhesion and reduced the ac-
tivity of RhoA, and ANXA2 may regulate F-actin
remodeling to affect the RhoA/ROCK signaling pathway,
thus promoting human placenta adhesion. In 2012,
Zhou et al. [35] reported that estrogen can lead to in-
creased expression of ANXA2 in an in vitro adenomyosis
model, and the increase in ANXA2 expression promoted
endometrial epithelial mesenchymal transformation. At
the same time, the increased expression of ANXA2 may
promote the angiogenesis activity of adenomyosis endo-
metrial cells through the HIF-1 alpha /VEGF-A pathway.
In 2014, through proteomic and immunohistochemical
analysis of recurrent and primary endometrial carcinoma,
Alonso et al. [26] determined that ANXA2 can be used as
a potential marker of endometrial carcinoma recurrence,
and ANXA2 causes a relapse through the promotion of
endometrial carcinoma metastasis, rather than its effect
on the sensitivity of radiotherapy and chemotherapy;
further knocking down of ANXA2 in a mouse model
led to a decreased spread of tumor cells circulating in
the blood; their retrospective studies have shown that
ANXA2 can effectively predict the recurrence ofendometrial carcinoma. Our research also showed that
the recurrence rate in ANXA2 high expression group
was significantly higher than ANXA2 low expression
group (Additional file 2: Table S1). ANXA2 expression
in endometrial carcinoma tissues can be used as an in-
dependent risk factor for prognosis; the prognostic risk
in patients with high expression of ANXA2 was eight
times higher than patients with low expression
(Table 3).
This study is the first study to examine the relation-
ship between the expression of ANXA2 in different
endometrial tissues and endometrial carcinoma clinico-
pathologic parameters, and to analyze the correlation be-
tween the expression of ANXA2 and HE4, suggesting that
ANXA2 and HE4 may play an important role in the prog-
nosis of endometrial carcinoma. Furthermore, the current
study found that in addition to ovarian cancer, ANXA2
and HE4 also interact in endometrial carcinoma, and co-
localized in the cell membrane and cytoplasm.
Conclusions
In summary, ANXA2 and HE4 were overexpressed in
endometrial carcinoma. The expression levels of ANXA2
and HE4 were positive correlated and the two proteins
played important roles in the process of endometrial ma-
lignant transformation. ANXA2 and HE4 can be used as
biomarkers to evaluate the prognosis of endometrial
carcinoma.
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Additional file 1: Figure S1. Representative images of different
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differentiation grade, FIGO stage III, scoring 3*4(ANXA2), 3*4(HE4); B.
serous adenocarcinoma, poor differentiation grade, FIGO stage I, scoring
2*2(ANXA2), 2*3(HE4); C. clear cell carcinoma, poor differentiation grade,
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poor differentiation grade, FIGO I, scoring 2*4(ANXA2),1.5*3(HE4); E.
squamous cell carcinoma, moderate differentiation grade, FIGO I, scoring
3*3(ANXA2), 2*4(HE4); F. mucinous adenocarcinoma, poor differentiation
grade, FIGO I, scoring 3*4(ANXA2), 1.5*3(HE4); G. small cell carcinoma,
poor differentiation grade, FIGO I, scoring 3*3(ANXA2), 3*4(HE4).
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